Alnylam Pharmaceuticals
ALNY
#628
Rank
C$43.35 B
Marketcap
$334.98
Share price
2.20%
Change (1 day)
67.88%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

EPS for Alnylam Pharmaceuticals (ALNY)

EPS in 2023 (TTM): -$5.50

According to Alnylam Pharmaceuticals 's latest financial reports the company's current EPS (TTM) is -$5.69. In 2022 the company made an earnings per share (EPS) of -$12.86 a decrease over its 2021 EPS that were of -$9.97.

EPS history for Alnylam Pharmaceuticals from 2003 to 2023

Annual EPS

Year EPS Change
2023 (TTM)-$5.50-57.26%
2022-$12.8629.03%
2021-$9.97-3.36%
2020-$10.31-8.48%
2019-$11.277.67%
2018-$10.4739.74%
2017-$7.4912.94%
2016-$6.6338.84%
2015-$4.78-32.88%
2014-$7.12259.44%
2013-$1.98-31.25%
2012-$2.8852.94%
2011-$1.8830.77%
2010-$1.44-8.77%
2009-$1.5878.13%
2008-$0.89-70.78%
2007-$3.0399.09%
2006-$1.52-43.88%
2005-$2.71-82.33%
2004-$15.36-59.23%
2003-$37.67

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
-$2.35-58.64%๐Ÿ‡บ๐Ÿ‡ธ USA
$51.72-1,009.00%๐Ÿ‡บ๐Ÿ‡ธ USA
-$10.84 90.51%๐Ÿ‡บ๐Ÿ‡ธ USA
-$0.37-93.43%๐Ÿ‡บ๐Ÿ‡ธ USA
-$2.34-58.88%๐Ÿ‡บ๐Ÿ‡ธ USA
$5.18-191.00%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
$4.40-177.38%๐Ÿ‡ซ๐Ÿ‡ท France
-$2.77-51.34%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel